Based on the provided data and technical analysis, here is the price prediction for EHC for next week:
Technical Analysis
- Current RSI(14) at 57.04 indicates neutral momentum, not showing overbought or oversold conditions
- MACD at 1.26 shows positive momentum
- Price is currently trading around its 20-day SMA of $97.19 and 60-day SMA of $97.51, suggesting a consolidation phase
- Fibonacci levels indicate key resistance at $102.77 and support at $96.04
News Analysis
- Recent Q4 2024 earnings showed strong performance with 12.7% revenue growth and significant improvements in adjusted EBITDA, EPS and free cash flow
- Company continues expansion plans with 7 new hospitals and 1 satellite facility planned for 2025, particularly in Florida market
- Analysts maintain bullish sentiment with Leerink Partners setting $119 price target, implying ~21% upside
- Stock showed resilience amid broader market decline, gaining 1.53% in recent trading
Price Prediction for Next Week
Based on technical indicators and positive fundamental backdrop:
- Base case (60% probability): $100-102 range
- Bullish case (25% probability): Break above $102.77 resistance toward $104.85
- Bearish case (15% probability): Pull back to support at $96.04
Recommendation: BUY
- Entry point: Current levels around $98-99
- Stop loss: Below $96 support
- Target: $102-104 range
- Catalysts: Continued execution on expansion plans and strong operational performance
The positive fundamental outlook, bullish analyst sentiment, and neutral-to-positive technical setup suggest upside potential with limited downside risk from current levels.
Based on the provided data and technical analysis, here is the price prediction for EHC for next week:
Technical Analysis
- Current RSI(14) at 57.04 indicates neutral momentum, not showing overbought or oversold conditions
- MACD at 1.26 shows positive momentum
- Price is currently trading around its 20-day SMA of $97.19 and 60-day SMA of $97.51, suggesting a consolidation phase
- Fibonacci levels indicate key resistance at $102.77 and support at $96.04
News Analysis
- Recent Q4 2024 earnings showed strong performance with 12.7% revenue growth and significant improvements in adjusted EBITDA, EPS and free cash flow
- Company continues expansion plans with 7 new hospitals and 1 satellite facility planned for 2025, particularly in Florida market
- Analysts maintain bullish sentiment with Leerink Partners setting $119 price target, implying ~21% upside
- Stock showed resilience amid broader market decline, gaining 1.53% in recent trading
Price Prediction for Next Week
Based on technical indicators and positive fundamental backdrop:
- Base case (60% probability): $100-102 range
- Bullish case (25% probability): Break above $102.77 resistance toward $104.85
- Bearish case (15% probability): Pull back to support at $96.04
Recommendation: BUY
- Entry point: Current levels around $98-99
- Stop loss: Below $96 support
- Target: $102-104 range
- Catalysts: Continued execution on expansion plans and strong operational performance
The positive fundamental outlook, bullish analyst sentiment, and neutral-to-positive technical setup suggest upside potential with limited downside risk from current levels.